Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,totalCashflowsFromInvestingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,trailingPE,epsTrailingTwelveMonths,currency,priceHint,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,exchange,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,country,website,maxAge,address1,industry
t0,HALB,-357956.0,0,,,64838,,64838,43181,137794,94613,94613,,-29897,,,,0,137794,43181,0,-29775,,64838,64838,682007.0,2250688.0,-357956.0,1892732.0,6366.0,-1046329.0,135.0,1456461.0,10596.0,1638042.0,254690.0,147969.0,794227.0,92998.0,45096.0,-2129.0,6765.0,6765.0,-190.0,-6955.0,31.0,-69695.0,,,,-1201771.0,en-US,US,EQUITY,False,Delayed Quote,2.656248,0.0312 - 0.0368,0.032,finmb_54016257,Other OTC,Halberd Corporation,USD,11141875,9816428,0.02905,7.644737,0.0038 - 0.109,-0.07615,-0.6986239,0.0038,0.109,10.95,0.003,USD,4,-0.014,0.031271428,0.0015785731,0.050479725,0.035399277,-0.0025492758,-0.07201491,2140013,-2.3464286,15,America/New_York,EDT,-14400000,PNK,0,False,False,0.03285,1630526377,0.0008499995,0.0313,0.0368,0.0312,3654927,HALBERD CORP,us_market,PREPRE,-8.76,,,0.109,0.0038,0.0313,0.0354,11.14M,9.82M,,,,0.00%,0.00%,,,,,,,,,,,0.00%,,,,,"Jul 30, 2011","Apr 29, 2012",26.63%,55.23%,9.41%,,270.76k,0.01,"174,322.80%",73.33k,139.91k,72.11k,0.0030,-60.10%,135,0,2.1M,,0.17,-0.01,-29.28k,-60.82k,Value,16133,Healthcare,"Halberd Corporation researches and develops antibodies and devices for the prevention, detection, and treatment of Covid-19 through laboratory, hospital, and clinical trials. It offers patented extracorporeal treatment that is applicable to various blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.",Jackson Center,814 786 8849,PA,United States,http://www.halberdcorporation.com,86400,P.O. Box 25,Biotechnology
t-1,HALB,-422794.0,0,,,21760,,21760,17975,53888,35913,35913,,-14275,,,,0,53888,17975,0,-14153,,21760,21760,682007.0,2247513.0,-422794.0,1824719.0,6366.0,-1111167.0,325.0,1450756.0,10596.0,1647132.0,177587.0,72917.0,796757.0,92998.0,45396.0,14239.0,3500.0,3500.0,-167.0,-3667.0,31.0,-39697.0,,,,-1273169.0,en-US,US,EQUITY,False,Delayed Quote,2.656248,0.0312 - 0.0368,0.032,finmb_54016257,Other OTC,Halberd Corporation,USD,11141875,9816428,0.02905,7.644737,0.0038 - 0.109,-0.07615,-0.6986239,0.0038,0.109,10.95,0.003,USD,4,-0.014,0.031271428,0.0015785731,0.050479725,0.035399277,-0.0025492758,-0.07201491,2140013,-2.3464286,15,America/New_York,EDT,-14400000,PNK,0,False,False,0.03285,1630526377,0.0008499995,0.0313,0.0368,0.0312,3654927,HALBERD CORP,us_market,PREPRE,-8.76,,,0.109,0.0038,0.0313,0.0354,11.14M,9.82M,,,,0.00%,0.00%,,,,,,,,,,,0.00%,,,,,"Jul 30, 2011","Apr 29, 2012",26.63%,55.23%,9.41%,,270.76k,0.01,"174,322.80%",73.33k,139.91k,72.11k,0.0030,-60.10%,135,0,2.1M,,0.17,-0.01,-29.28k,-60.82k,Value,16133,Healthcare,"Halberd Corporation researches and develops antibodies and devices for the prevention, detection, and treatment of Covid-19 through laboratory, hospital, and clinical trials. It offers patented extracorporeal treatment that is applicable to various blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.",Jackson Center,814 786 8849,PA,United States,http://www.halberdcorporation.com,86400,P.O. Box 25,Biotechnology
t-2,HALB,-444554.0,0,,,-15079,,-15079,43599,53042,9443,9443,,-24937,,,,0,53076,43633,34,-24522,,-15079,-15079,682007.0,2261081.0,-444554.0,1816527.0,6366.0,-1132927.0,492.0,1463732.0,10596.0,1656222.0,160305.0,54165.0,797349.0,92998.0,45096.0,9899.0,5000.0,5000.0,-149.0,-5149.0,31.0,-39697.0,,,,-1303427.0,en-US,US,EQUITY,False,Delayed Quote,2.656248,0.0312 - 0.0368,0.032,finmb_54016257,Other OTC,Halberd Corporation,USD,11141875,9816428,0.02905,7.644737,0.0038 - 0.109,-0.07615,-0.6986239,0.0038,0.109,10.95,0.003,USD,4,-0.014,0.031271428,0.0015785731,0.050479725,0.035399277,-0.0025492758,-0.07201491,2140013,-2.3464286,15,America/New_York,EDT,-14400000,PNK,0,False,False,0.03285,1630526377,0.0008499995,0.0313,0.0368,0.0312,3654927,HALBERD CORP,us_market,PREPRE,-8.76,,,0.109,0.0038,0.0313,0.0354,11.14M,9.82M,,,,0.00%,0.00%,,,,,,,,,,,0.00%,,,,,"Jul 30, 2011","Apr 29, 2012",26.63%,55.23%,9.41%,,270.76k,0.01,"174,322.80%",73.33k,139.91k,72.11k,0.0030,-60.10%,135,0,2.1M,,0.17,-0.01,-29.28k,-60.82k,Value,16133,Healthcare,"Halberd Corporation researches and develops antibodies and devices for the prevention, detection, and treatment of Covid-19 through laboratory, hospital, and clinical trials. It offers patented extracorporeal treatment that is applicable to various blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.",Jackson Center,814 786 8849,PA,United States,http://www.halberdcorporation.com,86400,P.O. Box 25,Biotechnology
t-3,HALB,-429475.0,0,,,587,,587,9682,19246,9564,9564,,-8977,,,,0,25998,16434,6752,-8977,,587,587,682007.0,547746.0,-429475.0,118271.0,6366.0,-1117848.0,641.0,547746.0,,1234.0,117037.0,23398.0,,92998.0,44796.0,9277.0,15409.0,15409.0,641.0,-13513.0,3621.0,-23398.0,-1255.0,-3600.0,-1255.0,-430709.0,en-US,US,EQUITY,False,Delayed Quote,2.656248,0.0312 - 0.0368,0.032,finmb_54016257,Other OTC,Halberd Corporation,USD,11141875,9816428,0.02905,7.644737,0.0038 - 0.109,-0.07615,-0.6986239,0.0038,0.109,10.95,0.003,USD,4,-0.014,0.031271428,0.0015785731,0.050479725,0.035399277,-0.0025492758,-0.07201491,2140013,-2.3464286,15,America/New_York,EDT,-14400000,PNK,0,False,False,0.03285,1630526377,0.0008499995,0.0313,0.0368,0.0312,3654927,HALBERD CORP,us_market,PREPRE,-8.76,,,0.109,0.0038,0.0313,0.0354,11.14M,9.82M,,,,0.00%,0.00%,,,,,,,,,,,0.00%,,,,,"Jul 30, 2011","Apr 29, 2012",26.63%,55.23%,9.41%,,270.76k,0.01,"174,322.80%",73.33k,139.91k,72.11k,0.0030,-60.10%,135,0,2.1M,,0.17,-0.01,-29.28k,-60.82k,Value,16133,Healthcare,"Halberd Corporation researches and develops antibodies and devices for the prevention, detection, and treatment of Covid-19 through laboratory, hospital, and clinical trials. It offers patented extracorporeal treatment that is applicable to various blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.",Jackson Center,814 786 8849,PA,United States,http://www.halberdcorporation.com,86400,P.O. Box 25,Biotechnology
